Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.8 USD | +2.98% | +11.76% | -1.04% |
05-14 | Transcript : Acumen Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 14, 2024 | |
05-08 | Acumen Pharmaceuticals Doses 1st Patient in Alzheimer's Disease Drug Study | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-1.04% | 222M | |
+29.77% | 49.18B | |
+1.00% | 42.11B | |
+50.47% | 40.37B | |
-5.26% | 28.85B | |
+13.68% | 26.09B | |
-22.99% | 18.71B | |
+8.22% | 13.26B | |
+32.41% | 12.32B | |
-1.62% | 11.99B |
- Stock Market
- Equities
- ABOS Stock
- News Acumen Pharmaceuticals, Inc.
- Credit Suisse Lowers Acumen Pharmaceuticals' PT to $17 from $26 on Updated Assumptions for ACU193 Pricing, FY Model Updates; Keeps Outperform Rating